Cargando…

What motivates Ebola survivors to donate plasma during an emergency clinical trial? The case of Ebola-Tx in Guinea

INTRODUCTION: During the 2014 Ebola Virus Disease (EVD) epidemic, the Ebola-Tx trial evaluated the use of convalescent plasma (CP) in Guinea. The effectiveness of plasmapheresis trials depends on the recruitment of plasma donors. This paper describes what motivated or deterred EVD survivors to donat...

Descripción completa

Detalles Bibliográficos
Autores principales: Ronse, Maya, Marí Sáez, Almudena, Gryseels, Charlotte, Bannister-Tyrrell, Melanie, Delamou, Alexandre, Guillard, Alain, Briki, Mustapha, Bigey, Frédéric, Haba, Nyankoye, van Griensven, Johan, Peeters Grietens, Koen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219816/
https://www.ncbi.nlm.nih.gov/pubmed/30332421
http://dx.doi.org/10.1371/journal.pntd.0006885
_version_ 1783368725968191488
author Ronse, Maya
Marí Sáez, Almudena
Gryseels, Charlotte
Bannister-Tyrrell, Melanie
Delamou, Alexandre
Guillard, Alain
Briki, Mustapha
Bigey, Frédéric
Haba, Nyankoye
van Griensven, Johan
Peeters Grietens, Koen
author_facet Ronse, Maya
Marí Sáez, Almudena
Gryseels, Charlotte
Bannister-Tyrrell, Melanie
Delamou, Alexandre
Guillard, Alain
Briki, Mustapha
Bigey, Frédéric
Haba, Nyankoye
van Griensven, Johan
Peeters Grietens, Koen
author_sort Ronse, Maya
collection PubMed
description INTRODUCTION: During the 2014 Ebola Virus Disease (EVD) epidemic, the Ebola-Tx trial evaluated the use of convalescent plasma (CP) in Guinea. The effectiveness of plasmapheresis trials depends on the recruitment of plasma donors. This paper describes what motivated or deterred EVD survivors to donate CP, providing insights for future plasmapheresis trials and epidemic preparedness. METHODS: This qualitative study, part of Ebola-Tx, researched and addressed emergent trial difficulties through interviewing, participant observation and focus group discussions. Sampling was theoretical and retroductive analysis was done in NVivo 10. RESULTS: Willingness or hesitance to participate in plasma donation depended on factors at the interface of pre-existing social dynamics; the impact of the disease and the consequent emergency response including the trial set-up. For volunteers, motivation to donate was mainly related to the feeling of social responsibility inspired by having survived EVD and to positive perceptions of plasmapheresis technology despite still unknown trial outcomes. Conversely, confidentiality concerns when volunteering due to stigmatization of survivors and perceived decrease in vital strength and in antibodies when donating, leading to fears of loss in protection against EVD, were main deterrents. The dynamic (dis)trust in Ebola Response Actors and in other survivors further determined willingness to participate and lead to the emergence/decline of rumours related to blood stealing and treatment effectiveness. Historic inter-ethnic relations in the health care setting further defined volunteering along socio-economic and ethnic lines. Finally, lack of follow-up and of dedicated care further impacted on motivation to volunteer. CONCLUSIONS: Ebola-Tx was the first trial to solicit and evaluate blood-product donation as an experimental treatment on a large scale in Sub-Saharan Africa. An effective donation system requires directly engaging with emergent social barriers and providing an effective ethical response, including improved and transparent communication, effective follow-up after donation, assuring confidentiality and determining ethical incentives.
format Online
Article
Text
id pubmed-6219816
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-62198162018-11-19 What motivates Ebola survivors to donate plasma during an emergency clinical trial? The case of Ebola-Tx in Guinea Ronse, Maya Marí Sáez, Almudena Gryseels, Charlotte Bannister-Tyrrell, Melanie Delamou, Alexandre Guillard, Alain Briki, Mustapha Bigey, Frédéric Haba, Nyankoye van Griensven, Johan Peeters Grietens, Koen PLoS Negl Trop Dis Research Article INTRODUCTION: During the 2014 Ebola Virus Disease (EVD) epidemic, the Ebola-Tx trial evaluated the use of convalescent plasma (CP) in Guinea. The effectiveness of plasmapheresis trials depends on the recruitment of plasma donors. This paper describes what motivated or deterred EVD survivors to donate CP, providing insights for future plasmapheresis trials and epidemic preparedness. METHODS: This qualitative study, part of Ebola-Tx, researched and addressed emergent trial difficulties through interviewing, participant observation and focus group discussions. Sampling was theoretical and retroductive analysis was done in NVivo 10. RESULTS: Willingness or hesitance to participate in plasma donation depended on factors at the interface of pre-existing social dynamics; the impact of the disease and the consequent emergency response including the trial set-up. For volunteers, motivation to donate was mainly related to the feeling of social responsibility inspired by having survived EVD and to positive perceptions of plasmapheresis technology despite still unknown trial outcomes. Conversely, confidentiality concerns when volunteering due to stigmatization of survivors and perceived decrease in vital strength and in antibodies when donating, leading to fears of loss in protection against EVD, were main deterrents. The dynamic (dis)trust in Ebola Response Actors and in other survivors further determined willingness to participate and lead to the emergence/decline of rumours related to blood stealing and treatment effectiveness. Historic inter-ethnic relations in the health care setting further defined volunteering along socio-economic and ethnic lines. Finally, lack of follow-up and of dedicated care further impacted on motivation to volunteer. CONCLUSIONS: Ebola-Tx was the first trial to solicit and evaluate blood-product donation as an experimental treatment on a large scale in Sub-Saharan Africa. An effective donation system requires directly engaging with emergent social barriers and providing an effective ethical response, including improved and transparent communication, effective follow-up after donation, assuring confidentiality and determining ethical incentives. Public Library of Science 2018-10-17 /pmc/articles/PMC6219816/ /pubmed/30332421 http://dx.doi.org/10.1371/journal.pntd.0006885 Text en © 2018 Ronse et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Ronse, Maya
Marí Sáez, Almudena
Gryseels, Charlotte
Bannister-Tyrrell, Melanie
Delamou, Alexandre
Guillard, Alain
Briki, Mustapha
Bigey, Frédéric
Haba, Nyankoye
van Griensven, Johan
Peeters Grietens, Koen
What motivates Ebola survivors to donate plasma during an emergency clinical trial? The case of Ebola-Tx in Guinea
title What motivates Ebola survivors to donate plasma during an emergency clinical trial? The case of Ebola-Tx in Guinea
title_full What motivates Ebola survivors to donate plasma during an emergency clinical trial? The case of Ebola-Tx in Guinea
title_fullStr What motivates Ebola survivors to donate plasma during an emergency clinical trial? The case of Ebola-Tx in Guinea
title_full_unstemmed What motivates Ebola survivors to donate plasma during an emergency clinical trial? The case of Ebola-Tx in Guinea
title_short What motivates Ebola survivors to donate plasma during an emergency clinical trial? The case of Ebola-Tx in Guinea
title_sort what motivates ebola survivors to donate plasma during an emergency clinical trial? the case of ebola-tx in guinea
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219816/
https://www.ncbi.nlm.nih.gov/pubmed/30332421
http://dx.doi.org/10.1371/journal.pntd.0006885
work_keys_str_mv AT ronsemaya whatmotivatesebolasurvivorstodonateplasmaduringanemergencyclinicaltrialthecaseofebolatxinguinea
AT marisaezalmudena whatmotivatesebolasurvivorstodonateplasmaduringanemergencyclinicaltrialthecaseofebolatxinguinea
AT gryseelscharlotte whatmotivatesebolasurvivorstodonateplasmaduringanemergencyclinicaltrialthecaseofebolatxinguinea
AT bannistertyrrellmelanie whatmotivatesebolasurvivorstodonateplasmaduringanemergencyclinicaltrialthecaseofebolatxinguinea
AT delamoualexandre whatmotivatesebolasurvivorstodonateplasmaduringanemergencyclinicaltrialthecaseofebolatxinguinea
AT guillardalain whatmotivatesebolasurvivorstodonateplasmaduringanemergencyclinicaltrialthecaseofebolatxinguinea
AT brikimustapha whatmotivatesebolasurvivorstodonateplasmaduringanemergencyclinicaltrialthecaseofebolatxinguinea
AT bigeyfrederic whatmotivatesebolasurvivorstodonateplasmaduringanemergencyclinicaltrialthecaseofebolatxinguinea
AT habanyankoye whatmotivatesebolasurvivorstodonateplasmaduringanemergencyclinicaltrialthecaseofebolatxinguinea
AT vangriensvenjohan whatmotivatesebolasurvivorstodonateplasmaduringanemergencyclinicaltrialthecaseofebolatxinguinea
AT peetersgrietenskoen whatmotivatesebolasurvivorstodonateplasmaduringanemergencyclinicaltrialthecaseofebolatxinguinea